Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fipravirimat + Dolutegravir vs. Dolutegravir + Lamivudine in Treatment-Naïve HIV-1
NCT04900038Phase 2Terminated
- Sponsor
- ViiV Healthcare
- Start
- Aug 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of fipravirimat in human immunodeficiency virus type 1 infection (HIV-1) (4 arms), sponsored by ViiV Healthcare. Primary endpoint: Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) Less Than (<)50 Copies Per Milliliter at 24 weeks. Started Aug 2021; status: terminated.
02
Drugs
fipravirimat
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04900038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04900038.